Literature DB >> 8274604

Empirical antibiotic therapy for fever in neutropenic patients.

G P Bodey1.   

Abstract

The necessity for administering empirical antibiotic therapy to febrile neutropenic patients has been well-established; however, no single regimen has been uniformly accepted. During the past decade, gram-positive organisms, often methicillin-resistant, have emerged as significant pathogens. The routine use of vancomycin may be appropriate at some institutions, but its widespread use may lead to resistance. The role of aminoglycosides as part of routine empirical regimens is controversial, and single extended-spectrum beta-lactam agents are often adequate therapy. Not all beta-lactam agents are equally effective, and some gram-negative pathogens, such as Xanthomonas maltophilia, are resistant to many of them. Pneumonia is frequent, the infecting pathogen is often undetermined, and therapy is unsatisfactory. Outpatient antibiotic therapy can be used in selected neutropenic patients. Empirical antibiotic regimens should be selected on the basis of knowledge about predominant pathogens and antibiotic susceptibilities at each institution as much as on the basis of studies from other institutions reported in the literature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274604     DOI: 10.1093/clinids/17.supplement_2.s378

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Management of febrile neutropenia in low risk cancer patients.

Authors:  B A Oppenheim; H Anderson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 2.  Sepsis and septic shock. II. Treatment.

Authors:  J Mayer; R Hajek; J Vorlicek; M Tomiska
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

Review 3.  Empirical therapy for bacterial infections in neutropenic patients.

Authors:  J Klastersky
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

4.  Infectious complications of combination anticancer chemotherapy for urogenital cancers.

Authors:  T Matsumoto; K Takahashi; M Tanaka; J Kumazawa
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 5.  Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.

Authors:  F de Lalla
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 6.  A guide to the treatment of lower respiratory tract infections.

Authors:  F Vogel
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

7.  TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values.

Authors:  J L Herrmann; H Blanchard; P Brunengo; P H Lagrange
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

8.  Computed tomography features of Stenotrophomonas maltophilia pneumonia in patients with neutropenic fever: report of two cases.

Authors:  Tsang Wai Kan Kassel; Lee Ka Lok Ryan; Allen Li
Journal:  Multidiscip Respir Med       Date:  2013-02-18

9.  Effect of Combination Therapy of Ceftazidime/Amikacin and Monotherapy with Imipenem on the Treatment of Fever and Neutropenia in Patients with Cancers.

Authors:  Ali Arash Anoshirvani; Nader Zarinfar; Mohammad Rafiee; Zahra Zamani
Journal:  Open Access Maced J Med Sci       Date:  2018-08-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.